CEO: Behind the scenes at Pharmaniaga

“The provision of RM552mil was made for 14 million doses of the Sinovac vaccine. We are talking with a big company to offtake half of the stock or seven million doses to be sold overseas. We expect to sign the agreement soon," said Zulkarnain.

ALMOST RM216mil or 38% of Pharmaniaga Bhd’s market capitalisation was wiped off in just a week, after a RM552mil vaccine provision sparked a panic among investors in the stock.

The pharmaceutical player had to make the provision for “slow-moving stocks of Covid-19 vaccines”, in accordance with accounting standards. This pulled the company into the red with a net loss of RM607.32mil in the financial year ended Dec 31, 2022 (FY22).

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 48
Cxense type: NA
User access status: 0
Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!

Pharmaniaga , vaccines , inventories , offload , Sinovac , PN17 , revenue


Next In Business News

Cryptoverse: Bitcoin passes the bank stress test
Khazanah Nasional hopes for wider options to decide on MAG
AICB, GEFI to jointly to host Ethical Finance Asean 2023 Summit
CMM launches CVC programme to spur investments in MSMEs
Malaysian banks are well positioned to face potential asset quality deterioration - RAM Ratings
Oil lower as banking turmoil holds down sentiment
Scientex enters JV in foray into Indonesian property project
Bursa gains as bank stocks retrace losses
Khazanah Nasional records RM1.6bil profit in FY22
Singapore second most expensive business location in Asia - ECA International

Others Also Read